It’s been just reported that there’s a company that is claiming patients who received the drug are twice as likely to recover compared to the ones who haven’t.
There’s a small study that finds potential hope in the treatment for the disease triggered by the novel coronavirus.
Fox News notes that the patients who had Covid-19 and inhaled interferon beta, a medicine that is usually used to treat severe diseases such as multiple sclerosis, had a 79% lower risk of developing more severe symptoms that could eventually lead to ventilation and even death.
The news is revealed by the study results announced Monday by the British company Synairgen.
SNG001 drug seems successful
It has been reported that the patients who received the drug, known as SNG001, were also twice as likely to recover compared to the once who received a placebo.
“We are all delighted with the trial results.”
It’s been revealed that the results “showed that SNG001 greatly reduced the number of hospitalized COVID-19 patients who progressed from ‘requiring oxygen’ to ‘requiring ventilation,'” the company’s CEO Richard Marsden stated.
Also, it’s important to note that the hospital stay for the people infected who took the treatment went from 9 days to 6 days.
An expert explained that interferon-beta “has huge potential as an inhaled drug to be able to restore the lung’s immune response, enhancing protection, accelerating recovery, and countering the impact of SARS-CoV-2 virus.”
More optimistic news
Just the other day, we were addressing the fact that there’s one new potential treatment for the novel coronavirus that has just been addressed.
Also, it’s important to mention the fact that an Italian infectious disease expert believes that the virus is becoming less and less dangerous, and it could eventually disappear without a vaccine, on its own.
There are also reports claiming that this could be the best solution to kill the pandemic.